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High level of anti-drug antibodies after
intra-articular injection of anti-TNF
Rheumatology key message
. Anti-drug antibodies against anti-TNF monoclonal
agents can appear even after a single intra-articular
infiltration.
SIR, Intra-articular injection of anti-TNF agents is not scien-
tifically validated but has been used empirically to treat
chronic synovitis. In the cases reported to date, the indica-
tion was recurrent inflammatory non-specific mono-arthritis
or mono-arthritis occurring in the context of axial spondy-
loarthritis [14]. Infliximab, etanercept or adalimumab has
been administered, either in anti-TNF-naı¨ve patients or in
patients treated with a different biologic agent [4]. In most
cases, the response was described as satisfactory and
sustained for several months. To our knowledge, there
have been few cases of repeated intra-articular injections
of anti-TNF agents [4] and no data on the induction of anti-
drug antibodies (ADABs) after intra-articular injection. The
measurement of ADABs against anti-TNF blockers has
become more widespread in recent years. ADABs were
found to be specific, and their levels correlated with a re-
sidual drug level and the loss of clinical response [5, 6].
We report the case of a 35-year-old patient with a non-
specific inflammatory mono-arthritis of the right knee that
did not respond to three consecutive intra-articular steroid
injections. The search for a specific rheumatic disease
was negative. It was decided, based on our own experi-
ence and the data in the literature, to inject the knee joint
with an anti-TNF. In March 2013, he received an intra-
articular injection of 100 mg of infliximab. The clinical re-
sponse was excellent, with rapid disappearance of joint
effusion for at least 6 months.
He returned 9 months later to request a second infiltra-
tion. We measured ADABs before the injection and found
very high ADABs to infliximab but not to adalimumab. We
injected the knee with the latter agent (40 mg) and once
again obtained an excellent result. Two months later,
there was a recurrence of effusion in the knee. Joint
fluid aspiration was performed and ADABs were mea-
sured in the SF and serum. Serum ADABs against inflix-
imab were still present but at a lower concentration than
the previous measurement, but this time ADABs against
adalimumab were also detected. The level of ADABs
against both medications was similar in the serum and
the SF (Fig. 1). He relapsed 10 months later. On this oc-
casion, etanercept (50 mg) was injected into the knee, and
once again an excellent response was obtained for
3 months. At that time, he did not develop ADABs against
this etanercept.
The case highlights the fact that ADABs can appear
even after a single intra-articular infiltration with an anti-
TNF agent and that ADABs diffuse from the joint to the
blood and vice versa. Moreover, the intra-articular expos-
ure to a second anti-TNF agent can also be followed by
the appearance of ADABs directed against this new
agent. Usually, ADABs in the blood do not appear after
a single contact with a new biologic. Some studies have
suggested that s.c. administration could enhance the risk
of developing ADABs because of the presence of antigen-
presenting cells in the skin [7]. Such cells are present in
even larger numbers within an inflamed synovial tissue.
The route of administration could therefore be responsible
for the rapid appearance ADABs leading to a rapid loss of
FIG. 1 Evolution of blood and joint fluid anti-drug antibodies against the different agents injected into the knee
ADABs cut-off for infliximab, adalimumab and etanercept: <10 mg/ml. ADAB: anti-drug antibodies.
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efficacy after repeated injections. It has also been sug-
gested that low dose and irregular injections may predis-
pose to ADABs and allergic reactions. This is consistent
with the findings in our case (long interval between the
injections and low dose of infliximab). Moreover, as aller-
gic reactions are known to be more frequent in the pres-
ence of ADABs [6], repeating such injections could
enhance the risk of an allergic reaction.
Rheumatologists should therefore be cautious about
the use of isolated intra-articular injections of TNF block-
ers. The authors think that measurement of ADABs should
be recommended after such a procedure, especially when
it is about to be repeated. The generation of ADABs fol-
lowing intra-articular monoclonal anti-TNF agents could
theoretically reduce the efficacy and enhance the toxicity
of subsequent systemic anti-TNF therapy.
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Comment on: High-risk pregnancy and the
rheumatologist
SIR, We read with great interest the recent paper by May
Ching Soh and Catherine Nelson-Piercy evaluating the
role of the rheumatologist for pregnant women with
rheumatic diseases [1]. Fertility, pregnancy, and manage-
ment of high-risk pregnancy are important topics for pa-
tients and their doctors alike. The paper offers a concise
overview of current basic and clinical research evidence
on the subject. However, we are concerned by the au-
thors’ claim regarding the use of cyclooxygenase-2
(COX-2) selective NSAIDs: ‘Data on the safety of COX-2
inhibitors in pregnancy are emerging, with a single popu-
lation-based study demonstrating no increased risk of
foetal malformation’ [1]. The quoted study [2] indeed re-
vealed that intrauterine exposure to NSAIDs in the first
trimester was not associated with an increased risk of
major congenital malformations. However, it did reveal
an increased risk for musculoskeletal malformations fol-
lowing exposure to COX-2 selective NSAIDs, with an ad-
justed odds ratio of 3.39 (95% CI 1.378.34) [2]. Although
this finding might be open to discussion due to the small
size of the exposed cohort, it might be prudent, until more
evidence arises, to exercise caution when prescribing
COX-2 selective NSAIDs in pregnant women.
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